BR112017021026A2 - novos métodos para seleção de epítopo. - Google Patents
novos métodos para seleção de epítopo.Info
- Publication number
- BR112017021026A2 BR112017021026A2 BR112017021026A BR112017021026A BR112017021026A2 BR 112017021026 A2 BR112017021026 A2 BR 112017021026A2 BR 112017021026 A BR112017021026 A BR 112017021026A BR 112017021026 A BR112017021026 A BR 112017021026A BR 112017021026 A2 BR112017021026 A2 BR 112017021026A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- antibody
- epitopes
- present
- epitope
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
a presente invenção se refere a determinados novos métodos para selecionar epítopos para anticorpos. a presente invenção também fornece um método para gerar um anticorpo (por exemplo, um anticorpo funcional) para uma proteína, em que o dito método compreende (i) identificar um epítopo antigênico na dita proteína expondo-se a proteína à proteólise limitada ou restrita colocando-se em contato a proteína com pelo menos uma protease para formar pelo menos uma versão digerida, desconstruída ou truncada da proteína e pelo menos um peptídeo de superfície exposta que é clivado da proteína pela ação da dita protease e que gera um epítopo antigênico com base no dito peptídeo de superfície exposta; e (ii) cultivar um anticorpo contra o epítopo antigênico. a presente invenção também fornece epítopos antigênicos e anticorpos contra tais epítopos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140955P | 2015-03-31 | 2015-03-31 | |
| US201562283118P | 2015-08-21 | 2015-08-21 | |
| PCT/EP2016/057164 WO2016156545A1 (en) | 2015-03-31 | 2016-03-31 | New methods for epitope selection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017021026A2 true BR112017021026A2 (pt) | 2018-11-06 |
Family
ID=55701934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017021026A BR112017021026A2 (pt) | 2015-03-31 | 2016-03-31 | novos métodos para seleção de epítopo. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11161901B2 (pt) |
| EP (1) | EP3277724A1 (pt) |
| JP (1) | JP6967507B2 (pt) |
| KR (1) | KR20170136551A (pt) |
| CN (1) | CN107531792A (pt) |
| AU (2) | AU2016240208B2 (pt) |
| BR (1) | BR112017021026A2 (pt) |
| CA (1) | CA2981108A1 (pt) |
| HK (1) | HK1249124A1 (pt) |
| IL (1) | IL254795B2 (pt) |
| MA (1) | MA41842A (pt) |
| MX (1) | MX2017012284A (pt) |
| NZ (1) | NZ735823A (pt) |
| RU (2) | RU2764992C2 (pt) |
| SG (1) | SG11201707945TA (pt) |
| WO (1) | WO2016156545A1 (pt) |
| ZA (1) | ZA201707369B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10753928B2 (en) | 2015-12-14 | 2020-08-25 | Morinaga Institute Of Biological Science, Inc. | Protein detection method, and protein immunoassay method |
| US11136362B2 (en) * | 2016-03-10 | 2021-10-05 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide modulators of specific calcineurin protein-protein interactions |
| GB201614884D0 (en) * | 2016-09-01 | 2016-10-19 | Oblique Therapeutics Ab | Method |
| GB201617002D0 (en) | 2016-10-06 | 2016-11-23 | Oblique Therapeutics Ab | Multi-protease method |
| CN107991495B (zh) * | 2017-11-27 | 2020-08-07 | 河南科技大学 | 一种提高膜蛋白序列检测覆盖率的质谱样品的制备方法 |
| JP6712369B2 (ja) * | 2018-05-29 | 2020-06-24 | 株式会社森永生科学研究所 | 抗ペプチド抗体の製造方法及び設計方法 |
| GB202019522D0 (en) * | 2020-12-10 | 2021-01-27 | Oblique Therapeutics Ab | Epitopes and antibodies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69133049T2 (de) * | 1990-10-18 | 2003-01-02 | Cancerforskningsfonden Af 1989 | Antikörper gegen den urokinaserezeptor und ihre verwendung |
| CN100387718C (zh) * | 1995-03-17 | 2008-05-14 | 益得生物医学公司 | 抗蛋白酶k降解的脑膜炎奈瑟氏球菌表面蛋白 |
| IL117483A (en) * | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| IL138946A0 (en) | 2000-10-11 | 2001-11-25 | Compugen Ltd | Method for the identification of peptides and proteins |
| HUP0400340A2 (hu) * | 2001-07-13 | 2004-08-30 | Merck Patent Gmbh. | Polipeptidek immunogenitásának csökkentésére szolgáló eljárások |
| AU2003287017B2 (en) * | 2002-10-03 | 2011-10-06 | Norman Leigh Anderson | High sensitivity quantitation of peptides by mass spectrometry |
| US7632686B2 (en) | 2002-10-03 | 2009-12-15 | Anderson Forschung Group | High sensitivity quantitation of peptides by mass spectrometry |
| MEP31508A (en) | 2003-07-15 | 2010-10-10 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| WO2005074923A1 (en) * | 2004-02-03 | 2005-08-18 | Agt Biosciences Limited | Methods and compositions |
| WO2006005472A1 (en) * | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1) |
| US20060292639A1 (en) * | 2004-08-13 | 2006-12-28 | Adolor Corporation | Splice variant of the vanilloid receptor VR1A |
| WO2006047417A2 (en) * | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
| SE0403139D0 (sv) | 2004-12-23 | 2004-12-23 | Nanoxis Ab | Device and use thereof |
| JP2008175814A (ja) * | 2006-12-21 | 2008-07-31 | Eisai R & D Management Co Ltd | 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット |
| WO2008120684A1 (ja) * | 2007-03-30 | 2008-10-09 | Yamaguchi University | 急性中枢神経障害の予後判定方法 |
| AR071698A1 (es) | 2008-05-09 | 2010-07-07 | Abbott Gmbh & Co Kg | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos |
| US20120128646A1 (en) | 2009-02-17 | 2012-05-24 | Kathryn Haskins | Methods and compositions for the treatment of autoimmune disease |
| US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
| US9383367B1 (en) | 2010-12-07 | 2016-07-05 | Chunli Liu | Methods of detecting conjugation site-specific and hidden epitope/antigen |
| WO2013020557A1 (en) | 2011-08-08 | 2013-02-14 | Syddansk Universitet | Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination |
| AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
| GB201617002D0 (en) | 2016-10-06 | 2016-11-23 | Oblique Therapeutics Ab | Multi-protease method |
-
2016
- 2016-03-30 MA MA041842A patent/MA41842A/fr unknown
- 2016-03-31 SG SG11201707945TA patent/SG11201707945TA/en unknown
- 2016-03-31 US US15/562,610 patent/US11161901B2/en active Active
- 2016-03-31 MX MX2017012284A patent/MX2017012284A/es unknown
- 2016-03-31 AU AU2016240208A patent/AU2016240208B2/en active Active
- 2016-03-31 RU RU2017134875A patent/RU2764992C2/ru active
- 2016-03-31 JP JP2018502331A patent/JP6967507B2/ja active Active
- 2016-03-31 IL IL254795A patent/IL254795B2/en unknown
- 2016-03-31 CN CN201680025162.8A patent/CN107531792A/zh active Pending
- 2016-03-31 EP EP16715482.2A patent/EP3277724A1/en active Pending
- 2016-03-31 NZ NZ735823A patent/NZ735823A/en unknown
- 2016-03-31 CA CA2981108A patent/CA2981108A1/en active Pending
- 2016-03-31 KR KR1020177031120A patent/KR20170136551A/ko not_active Application Discontinuation
- 2016-03-31 BR BR112017021026A patent/BR112017021026A2/pt active Search and Examination
- 2016-03-31 WO PCT/EP2016/057164 patent/WO2016156545A1/en active Application Filing
- 2016-03-31 RU RU2022100590A patent/RU2022100590A/ru unknown
-
2017
- 2017-10-30 ZA ZA2017/07369A patent/ZA201707369B/en unknown
-
2018
- 2018-07-11 HK HK18109009.0A patent/HK1249124A1/zh unknown
-
2021
- 2021-09-29 US US17/488,692 patent/US11912765B2/en active Active
-
2022
- 2022-04-04 AU AU2022202251A patent/AU2022202251A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017134875A (ru) | 2019-05-06 |
| JP2018509942A (ja) | 2018-04-12 |
| WO2016156545A1 (en) | 2016-10-06 |
| MX2017012284A (es) | 2018-06-20 |
| NZ735823A (en) | 2023-07-28 |
| JP6967507B2 (ja) | 2021-11-17 |
| AU2022202251A1 (en) | 2022-04-21 |
| IL254795A0 (en) | 2017-12-31 |
| AU2016240208A1 (en) | 2017-10-19 |
| RU2764992C2 (ru) | 2022-01-24 |
| IL254795B1 (en) | 2023-05-01 |
| MA41842A (fr) | 2018-02-06 |
| IL254795B2 (en) | 2023-09-01 |
| CA2981108A1 (en) | 2016-10-06 |
| US20180111990A1 (en) | 2018-04-26 |
| AU2016240208B2 (en) | 2022-01-27 |
| US20220073607A1 (en) | 2022-03-10 |
| RU2017134875A3 (pt) | 2019-09-13 |
| KR20170136551A (ko) | 2017-12-11 |
| EP3277724A1 (en) | 2018-02-07 |
| RU2022100590A (ru) | 2022-03-10 |
| SG11201707945TA (en) | 2017-10-30 |
| US11912765B2 (en) | 2024-02-27 |
| CN107531792A (zh) | 2018-01-02 |
| ZA201707369B (en) | 2019-02-27 |
| HK1249124A1 (zh) | 2018-10-26 |
| US11161901B2 (en) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017021026A2 (pt) | novos métodos para seleção de epítopo. | |
| CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
| CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
| CO2021002907A2 (es) | Constructos de anticuerpos para cldn18.2 y cd3 | |
| BR112017026330A2 (pt) | molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
| BR112018000475A2 (pt) | construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3 | |
| CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| BR112018001531A2 (pt) | construtos de anticorpo para cd70 e cd3 | |
| BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
| ECSP19005417A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| BR112019002579A2 (pt) | anticorpos biespecíficos fab monovalentes, assimétricos e tandem | |
| BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
| BR112013027829A2 (pt) | anticorpos anti-cd40 e método de uso | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| GT201200298A (es) | Composiciones y método de uso terapéutico para anticuerpos multivalentes de lrp6 (proteína relacionada con lipoproteínas de baja densidad 6) | |
| AR106188A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| BR112016019057A2 (pt) | método de induzir uma resposta imune contra uma doença em um indivíduo | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| BR112021025438A2 (pt) | Composições de proteínas anti-vegf e métodos para produzir as mesmas | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| BR112022001693A2 (pt) | Construtos de proteína de ligação ao antígeno e usos dos mesmos | |
| BR112022008730A2 (pt) | Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo | |
| CL2023000595A1 (es) | Anticuerpo que se une a vegf-a y ang2, y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |